

Impact of the Common Genetic Associations of Age-Related Macular Degeneration upon Systemic Complement Component C3d Levels

Tina Ristau¹, Constantin Paun², Lebriz Ersoy¹, Moritz Hahn³, Yara Lechanteur², Carel Hoyng², Eiko K. de Jong², Mohamed R. Daha⁴, Bernd Kirchhof¹, Anneke I. den Hollander², Sascha Fauser^{1*}

1 Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany, **2** Department of Ophthalmology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands, **3** Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany, **4** Department of Nephrology, Leiden University Nijmegen Medical Center, Leiden, the Netherlands

Abstract

Age-related macular degeneration (AMD) is a common condition that leads to severe vision loss and dysregulation of the complement system is thought to be associated with the disease. To investigate associations of polymorphisms in AMD susceptibility genes with systemic complement activation, 2655 individuals were genotyped for 32 single nucleotide polymorphisms (SNPs) in or near 23 AMD associated risk genes. Component 3 (C3) and its catabolic fragment C3d were measured in serum and AMD staging was performed using multimodal imaging. The C3d/C3 ratio was calculated and associations with environmental factors, SNPs and various haplotypes of *complement factor H (CFH)* genes and *complement factor B (CFB)* genes were analyzed. Linear models were built to measure the influence of genetic variants on the C3d/C3 ratio. The study cohort included 1387 patients with AMD and 1268 controls. Higher C3d/C3 ratios were found for current smoker ($p=0.002$), higher age ($p=1.56\times 10^{-7}$), AMD phenotype ($p=1.15\times 10^{-11}$) and the two SNPs in the C3 gene rs6795735 ($p=0.04$) and rs2230199 ($p=0.04$). Lower C3d/C3 ratios were found for diabetes ($p=2.87\times 10^{-6}$), higher body mass index ($p=1.00\times 10^{-13}$), the SNPs rs1410996 ($p=0.0001$), rs800292 ($p=0.003$), rs12144939 ($p=4.60\times 10^{-6}$) in *CFH*, rs4151667 ($p=1.01\times 10^{-5}$) in *CFB* and individual haplotypes in *CFH* and *CFB*. The linear model revealed a corrected R-square of 0.063 including age, smoking status, gender, and genetic polymorphisms explaining 6.3% of the C3d/C3 ratio. After adding the AMD status the corrected R-square was 0.067. In conclusion, none of the evaluated genetic polymorphisms showed an association with increased systemic complement activation apart from two SNPs in the C3 gene. Major genetic and non-genetic factors for AMD were not associated with systemic complement activation.

Citation: Ristau T, Paun C, Ersoy L, Hahn M, Lechanteur Y, et al. (2014) Impact of the Common Genetic Associations of Age-Related Macular Degeneration upon Systemic Complement Component C3d Levels. PLoS ONE 9(3): e93459. doi:10.1371/journal.pone.0093459

Editor: Keisuke Mori, Saitama Medical University, Japan

Received: January 23, 2014; **Accepted:** March 6, 2014; **Published:** March 27, 2014

Copyright: © 2014 Ristau et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Retinovit Foundation, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: sascha.fauser@uk-koeln.de

Introduction

Age-related macular degeneration (AMD) is a neurodegenerative disease causing visual impairment and blindness in the elderly population. Accumulation of drusen between Bruch's membrane and the retinal pigment epithelium characterizes the early forms while the two advanced forms show geographic atrophy and choroidal neovascularization. Risk is multifactorial including environmental and genetic factors. Genetic variation accounts for up to 71% of the disease risk [1]. Many genetic polymorphisms were found in the alternative pathway of the complement system including *complement factor H (CFH)*, *complement component 3 (C3)*, *Complement factor I (CFI)*, and *complement factor B (C2/CFB locus)* [2–8]. Complement proteins and their activation products have been identified in retinal deposits of AMD patients [3,9–11].

The alternative complement pathway is constantly activated by the spontaneous hydrolysis of a thioester bond in C3 and a tight regulation including CFH is necessary to prevent excessive

activation. It is hypothesized that a dysregulation of the complement system leads to tissue damage and finally AMD.

The dysregulation of the complement system or their activation fragments were also found systemically. In AMD patients, various components of the complement system were found at increased levels such as CFB, CFD, C3a, C5a, C3d, and Ba [12,13].

While the association of genetic polymorphisms with AMD is well established, only polymorphisms in the C3 gene and few haplotypes in the CFH and CFB/C2 gene were found to be associated with complement activation products including factor C3d in two small cohorts [12,13]. The impact of other AMD susceptibility genes on the regulation of systemic complement activation remains unclear. In our study, we analyzed the association of 32 single nucleotide polymorphisms (SNPs) in or near 23 AMD risk genes with the C3d/C3 ratio as a marker for chronic complement activation in a Caucasian cohort of 2655 participants.

Table 1. Median C3d/C3 ratios for non-genetic factors.

Non-genetic factor	N (%)	Median C3d/C3 ratio (IQR)	T-test/univariate ANOVA
Female sex	1547 (58.3)	0.00424 (0.00325–0.00561)	0.90
Male sex	1108 (41.7)	0.00433 (0.00328–0.00567)	
Age 50–59 years	61 (2.3)	0.00430 (0.00337–0.00598)	1.56 × 10 ⁻⁷
Age 60–69 years	879 (33.1)	0.00408 (0.00312–0.00550)	
Age 70–79 years	1140 (42.9)	0.00426 (0.00324–0.00547)	
Age 80–89 years	474 (17.9)	0.00462 (0.00356–0.00591)	
Age 90–99 years	97 (3.7)	0.00488 (0.00374–0.00705)	
No AMD	1268 (47.8)	0.00403 (0.00309–0.00536)	1.15 × 10 ⁻¹¹
AMD	1387 (52.2)	0.00449 (0.00348–0.00586)	
No arterial hypertension	1600 (63.6)	0.00428 (0.00328–0.00563)	0.24
Arterial hypertension	917 (36.4)	0.00425 (0.00321–0.00556)	
No diabetes	2268 (90.8)	0.00430 (0.00330–0.00567)	2.87 × 10 ⁻⁶
Diabetes	231 (9.2)	0.00390 (0.00295–0.00495)	
No rheumatoid arthritis	2353 (93.5)	0.00426 (0.00327–0.00559)	0.35
Rheumatoid arthritis	164 (6.5)	0.00433 (0.00304–0.00564)	
No thyroid disease	2119 (84.2)	0.00426 (0.00326–0.00559)	0.77
Thyroid disease	398 (15.8)	0.00429 (0.00325–0.00559)	
No kidney disease	2403 (95.5)	0.00426 (0.00326–0.00559)	0.92
Kidney disease	114 (4.5)	0.00447 (0.00320–0.00572)	
No allergy	1984 (78.8)	0.00428 (0.00325–0.00562)	0.75
Allergy	533 (21.2)	0.00425 (0.00328–0.00552)	
Never smoker	1029 (43.0)	0.00431 (0.00325–0.00572)	0.002
Past smoker	1164 (48.6)	0.00415 (0.00320–0.00545)	
Current smoker	201 (8.4)	0.00451 (0.00355–0.00584)	
BMI <25	930 (40.1)	0.00464 (0.00360–0.00611)	1.00 × 10 ⁻¹³
BMI 25–29	1084 (46.7)	0.00408 (0.00312–0.00531)	
BMI ≥30	308 (13.3)	0.00376 (0.00287–0.00493)	

IQR = interquartile range (1st quartile – 3rd quartile).
doi:10.1371/journal.pone.0093459.t001

Methods

Study population

2655 participants from the European Genetic Database (EUGENDA, www.eugenda.org) were included in the study. The study was performed in accordance with the tenets of the Declaration of Helsinki and the Medical Research Involving Human Subjects Act (WMO) and was approved by the local ethics committee of the University Hospitals in Cologne and Nijmegen. Written informed consent was obtained from all participants.

AMD staging was performed by grading of retinal images including stereo fundus photographs (FPs), fluorescein angiograms (FAs) and spectral domain optical coherence tomograms (SDOCTs) according to the standard protocol of the Cologne Image Reading Center (CIRCL) by certified graders (TR, LE). AMD was classified by the presence of pigmentary changes together with at least 10 small drusen (<63 μm) or the presence of intermediate (63–124 μm) or large drusen (≥125 μm diameter) in the Early Treatment Diabetic Maculopathy Study (ETDRS) grid or geographic atrophy and/or choroidal neovascularisation (CNV) secondary to AMD in at least one eye.

Demographic data and non-genetic parameters including history of smoking (current/past/never), regular alcohol intake (yes/no), body mass index (BMI), arterial hypertension (yes/no),

diabetes (yes/no), rheumatoid arthritis (yes/no), thyroid disease (yes/no), kidney disease (yes/no) and history of allergy (yes/no) were obtained by standardized interviewer-assisted questionnaires.

Complement component measurements and genetic analysis

Serum samples were used for C3d and C3 measurements. Serum was prepared by coagulation at room temperature. After centrifugation, the samples were stored at –80°C within 1 hour after collection. Complement component C3 and the activation fragment C3d were measured in serum samples as described previously [14]. The C3d/C3 ratio was calculated as a measure of C3 activation.

Genomic DNA was extracted from peripheral blood samples using standard procedures. Thirty-two SNPs in or near 23 AMD associated risk genes were chosen representing the majority of loci associated with AMD. Genotyping of SNPs in the *ARMS2* (rs10490924), *CFH* (rs1061170, rs800292, rs12144939, rs1410996), *CFI* (rs10033900, rs141853578), *C2* (rs9332739), *C3* (rs2230199, rs433594, rs6795735), *CFB* (rs4151667, rs641153), *CFD* (rs3826945), *LPL* (rs12678919), *LIPC* (rs10468017), *TIMP3* (rs9621532), *APOE2* (rs7412), *APOE4* (rs429358), *FADS1* (rs174547), *CETP* (rs2230199), *TLR* (rs4986790, rs3775291),

Table 2. Median C3d/C3 ratios for single nucleotide polymorphisms (SNPs).

SNP	Homozygous non-variant (n)	Heterozygous variant (n)	Homozygous variant (n)	Median C3d/C3 ratio homozygous non-variant (IQR)	Median C3d/C3 ratio heterozygous variant (IQR)	Median C3d/C3 ratio homozygous variant (IQR)	Univariate ANOVA
ARMS2	GG = 1039	GT = 825	TT = 241	0.00425 (0.00338–0.00589)	0.00416 (0.00320–0.00556)	0.00446 (0.00336–0.00593)	0.31
rs10490924							
CFH	TT = 690	TC = 967	CC = 436	0.00425 (0.00320–0.00560)	0.00418 (0.00323–0.00546)	0.00433 (0.00335–0.00561)	0.66
rs1061170							
CFH	CC = 459	CT = 453	TT = 113	0.00436 (0.00334–0.00570)	0.00404 (0.00310–0.00529)	0.00355 (0.00209–0.00491)	0.0001
rs1410996							
CFH	GG = 1177	GA = 608	AA = 95	0.00427 (0.00329–0.00567)	0.00406 (0.00312–0.00535)	0.00394 (0.00319–0.00516)	0.003
rs800292							
CFH	GG = 1290	GT = 537	TT = 64	0.00435 (0.00329–0.00570)	0.00390 (0.00305–0.00510)	0.00373 (0.00287–0.00469)	4.60×10^{-6}
rs12144939							
CFI	TT = 499	TC = 1056	CC = 547	0.00426 (0.00324–0.00570)	0.00420 (0.00324–0.00553)	0.00424 (0.00325–0.00547)	0.80
rs10033900							
CFI	GG = 1862	GA = 10	AA = 0	0.00419 (0.00321–0.00553)	0.00485 (0.00415–0.00673)	N/A	0.18
rs141853578							
C2	CC = 927	CG = 70	GG = 0	0.00422 (0.00320–0.00544)	0.00362 (0.00299–0.00492)	N/A	0.05
rs9332739							
C3	CC = 1300	GC = 713	GG = 115	0.00415 (0.00319–0.00549)	0.00432 (0.00334–0.00561)	0.00432 (0.00327–0.00627)	0.04
rs2230199							
C3	CC = 723	CT = 900	TT = 261	0.00420 (0.00320–0.00557)	0.00420 (0.00323–0.00555)	0.00421 (0.00328–0.00548)	0.81
rs433594							
C3	GG = 1197	GA = 617	AA = 84	0.00413 (0.00317–0.00549)	0.00424 (0.00333–0.00550)	0.00448 (0.00333–0.00640)	0.04
rs6795735							
CFB	TT = 1958	TA = 160	AA = 2*	0.00428 (0.00327–0.00562)	0.00358 (0.00297–0.00472)	0.00497 (N/A)	1.01×10^{-5}
rs4151667							
CFB	GG = 1616	GA = 265	AA = 7*	0.00421 (0.00324–0.00556)	0.00414 (0.00314–0.00559)	0.00311 (0.00223–0.00335)	0.69
rs641153							
CFD	TT = 488	TC = 407	CC = 93	0.00404 (0.00320–0.00542)	0.00421 (0.00319–0.00531)	0.00413 (0.00308–0.00525)	0.95
rs3826945							
LPL	AA = 1705	AG = 388	GG = 31	0.00423 (0.00321–0.00561)	0.00423 (0.00338–0.00542)	0.00479 (0.00342–0.00593)	0.89
rs12678919							
LIPC	CC = 1057	CT = 888	TT = 144	0.00421 (0.00322–0.00546)	0.00423 (0.00322–0.00562)	0.00441 (0.00337–0.00558)	0.46
rs10468017							
TIIMP3	AA = 882	AC = 77	CC = 7*	0.00411 (0.00318–0.00531)	0.00425 (0.00332–0.00543)	0.00392 (0.00376–0.00584)	0.70
rs9621532							

Table 2. Cont.

SNP	Homozygous non-variant (n)	Heterozygous variant (n)	Homozygous variant (n)	Median C3d/C3 ratio homozygous non-variant (IQR)	Median C3d/C3 ratio heterozygous variant (IQR)	Median C3d/C3 ratio homozygous variant (IQR)	Univariate ANOVA
APOE2	CC = 804	CT = 160	TT = 12	0.00420 (0.00322–0.00543)	0.00393 (0.00306–0.00524)	0.00417 (0.00301–0.00485)	0.53
rs7412							
APOE4	TT = 689	TC = 195	CC = 9*	0.00420 (0.00320–0.00537)	0.00396 (0.00311–0.00530)	0.00272 (0.00253–0.00609)	0.49
rs429358							
FADS1	TT = 995	TC = 924	CC = 209	0.00432 (0.00330–0.00567)	0.00416 (0.00319–0.00557)	0.00394 (0.00334–0.00508)	0.05
rs174547							
CETP	GG = 997	GT = 906	TT = 246	0.00420 (0.00328–0.00559)	0.00424 (0.00320–0.00546)	0.00428 (0.00324–0.00568)	0.91
rs2230199							
TLR	AA = 872	AG = 119	GG = 5	0.00419 (0.00319–0.00539)	0.00408 (0.00333–0.00530)	0.00283 (0.00248–0.00441)	0.24
rs4986790							
TLR3	CC = 497	CT = 380	TT = 86	0.00401 (0.00306–0.00561)	0.00420 (0.00333–0.00513)	0.00430 (0.00320–0.00594)	0.31
rs3775291							
SERPING	GG = 322	GA = 485	AA = 183	0.00410 (0.00317–0.00529)	0.00410 (0.00322–0.00542)	0.00428 (0.00316–0.00546)	0.56
rs2511989							
ABCA4	GG = 985	GA = 15	AA = 0	0.00418 (0.00319–0.00538)	0.00368 (0.00337–0.00440)	N/A	0.17
rs1800555							
ABCA4	GG = 975	GA = 4	AA = 0	0.00415 (0.00320–0.00538)	0.00447 (0.00289–0.00659)	N/A	0.87
rs1800553							
ABCA4	GG = 1854	CG = 31	CC = 0	0.00419 (0.00321–0.00556)	0.00443 (0.00332–0.00521)	N/A	0.81
rs76157638							
VEGFA	AA = 629	AG = 322	GG = 42	0.00425 (0.00327–0.00543)	0.00400 (0.00303–0.00540)	0.00376 (0.00324–0.00467)	0.14
rs699946							
SPRYD7	TT = 714	TC = 220	CC = 21	0.00418 (0.00322–0.00537)	0.00433 (0.00317–0.00558)	0.00390 (0.00255–0.00503)	0.30
rs7995557							
COL8A1	GG = 1545	GT = 333	TT = 13	0.00421 (0.00322–0.00558)	0.00420 (0.00321–0.00543)	0.00502 (0.00342–0.00566)	0.73
rs13081855							
COL10A1	AA = 742	AT = 899	TT = 241	0.00424 (0.00319–0.00555)	0.00411 (0.00323–0.00548)	0.00440 (0.00330–0.00575)	0.87
rs3812111							
SLC16A8	CC = 1155	CT = 632	TT = 86	0.00421 (0.00324–0.00556)	0.00420 (0.00319–0.00556)	0.00423 (0.00312–0.00563)	0.83
rs8135665							
ADAMTS9	CC = 647	CT = 898	TT = 343	0.00425 (0.00320–0.00572)	0.00419 (0.00325–0.00540)	0.00412 (0.00313–0.00561)	0.57
rs6795735							

*Due to small number of cases excluded from univariate ANOVA analysis; IQR = interquartile range (1st quartile – 3rd quartile).
doi:10.1371/journal.pone.0093459.t002




Figure 1. Logarithmic C3d/C3 ratios for haplotypes in the *CFH* gene rs1061170, rs800292 and rs12144939.
doi:10.1371/journal.pone.0093459.g001




Figure 2. Logarithmic C3d/C3 ratios for haplotypes in the *CFB* gene rs4151667 and rs641153.
doi:10.1371/journal.pone.0093459.g002

Table 3. Haplotypes for *CFH/CFB* and median C3d/C3 ratios.

Haplotype CFH	n	Haplotype frequency	MedianC3d/C3 ratio (IQR)	T-test
TGG	728	0.20	0.00456 (0.00345–0.00608)	.*
CGG	1544	0.42	0.00420 (0.00324–0.00550)	1.40×10^{-8}
TAG	755	0.20	0.00405 (0.00314–0.00530)	3.61×10^{-12}
TGT	620	0.17	0.00386 (0.00300–0.00504)	1.03×10^{-13}
CAG	21	0.008	0.00396 (0.00339–0.00507)	.**
TAT	18	0.005	0.00386 (0.00317–0.00513)	.**
Haplotype CFB	n	Haplotype frequency	MedianC3d/C3 ratio (IQR)	T-test
TG	3337	0.89	0.00424 (0.00325–0.00559)	.*
TA	279	0.07	0.00408 (0.00310–0.00546)	0.15
AG	152	0.04	0.00356 (0.00292–0.00471)	9.96×10^{-6}

For *CFH* single nucleotides polymorphisms rs1061170, rs800292, and rs12144939 and for *CFB* rs4151667 and rs641153 were chosen.

*T- test with comparison to reference haplotypes TGG and TG; **Due to small number of cases excluded from analysis; IQR = interquartile range (1st quartile – 3rd quartile).

doi:10.1371/journal.pone.0093459.t003

SERPINE1 (rs2511989), *ABCA4* (rs1800555, rs1800553, rs76157638), *VEGFA* (rs699946), *SPRYD7* (rs7995557), *COL8A1* (rs13081855), *COL10A1* (rs3812111), *SLC16A8* (rs8135665), *ADAMTS9-AS2* (rs6795735) genes were carried out as previously described [15].

Haplotype analysis

In order to analyze the influence of haplotypes on C3d/C3 ratios, the posterior probability of each haplotype in the *CFH* gene including rs1061170, rs800292 and rs12144939 and in the *CFB* gene including rs4151667 and rs641153 was calculated using PHASE software, version 2.1 [16,17].

Statistical analysis

All calculations were performed using SPSS software version 21.0 (IBM Software and Systems, Armonk, NY, USA). C3d/C3 ratios are given as median and interquartile range (1st quartile – 3rd quartile). Due to the skewed nature of the data, the logarithm (\log_{10}) of the C3d/C3 ratios was used for analysis. Associations between logarithmic C3d/C3 ratios and genetic polymorphisms, haplotypes, phenotype and environmental factors were analyzed using t-tests or univariate analysis of variance (ANOVA) depending on number of variables. Associations between AMD phenotype and genetic polymorphisms were evaluated using logistic regression analysis. Linear models were performed to illustrate the influence of the genetic factors on complement activation. P-Values <0.05 were considered statistically significant.

Results

Demographics and non-genetic factors

Mean age of the study population was 73.2 ± 8.0 years (75.8 ± 8.1 years for AMD patients and 70.4 ± 6.8 years for controls, $p < 0.001$). Demographic data, phenotype and environmental factors are summarized in Table 1. C3d/C3 ratios showed significant differences for age with increasing levels (except the youngest group from 50–59 years) and phenotype with higher values for AMD patients. A significant association was also found for diabetes, smoking, and BMI.

Associations of C3d/C3 levels with genetic polymorphisms

Significant associations of C3d/C3 levels were found in the *CFH* gene for the SNPs rs1410996, rs800292 and rs12144939, in the *CFB* gene for rs4151667 and in the *C3* gene for rs6795735 and rs2230199. In all SNPs of the *CFH* and *CFB* gene, these variants showed lower C3d/C3 ratios than the reference alleles, only variants in *C3* revealed higher values. After stratification in AMD cases and controls, associations for the major risk variants in rs1061170 (*CFHY402H*, $p = 0.35$ for no AMD; $p = 0.55$ for AMD) and rs10490924 (*ARMS2*, $p = 0.75$ for No AMD, $p = 0.25$ for AMD) with the C3d/C3 ratio could not be observed. A detailed analysis is outlined in Table 2.

For the SNPs rs1061170, rs800292 and rs12144939 in the *CFH* gene and the SNPs rs4151667 and rs641153 in the *CFB* gene, haplotypes were associated with C3d/C3 levels (Table 3). All haplotypes were associated with lower C3d/C3 levels than the reference haplotype (Figure 1 and 2).

Associations of genetic polymorphisms with AMD

Performing logistic regression analysis, protective effects were found for variants in *CFH* rs1410996, *CFH* rs800292, *CFH* rs12144939, *CFB* rs641153 and *FADS1* rs174547. Variants in *CFB* rs4151667, *TIMP3* rs9621532 and *APOE4* rs429358 showed a trend for a protective effect on AMD without reaching statistical significance, which may be due to low minor allele frequencies or smaller effects of those SNPs.

Variants in *ARMS2* rs10490924, *CFH* rs1061170, *C3* rs2230199, *C3* rs6795735 and *CETP* rs2230199 were found to be associated with significantly higher risk for AMD (Table 4). Variants in *VEGFA* rs699946, *SLC16A8* rs8135665 and *ADAMTS9-AS2* rs6795735 also showed a trend for a higher AMD risk without statistical significance, which also may be due to a smaller effect on AMD development for each of those SNPs compared to *ARMS2* rs10490924 or *CFH* rs1061170.

Linear Models

Linear models were composed based on univariate analysis of covariance (ANCOVA) with the logarithmic C3d/C3 ratio as dependent variable to evaluate the influence of various factors on the C3d/C3 ratio. In the first model, we included all SNPs (rs1410996, rs800292, rs12144939 in *CFH*, rs4151667 in *CFB*,

Table 4. Logistic regression analysis between AMD and single nucleotide polymorphisms SNPs[†].

SNP	Heterozygous variant			Homozygous variant		
	OR	95% CI	P-value	OR	95% CI	P-value
ARMS2 rs10490924	2.32	1.90–2.84	1.00×10 ⁻¹³	8.13	5.66–11.69	1.00×10 ⁻¹³
CFH rs1061170	1.57	1.27–1.95	3.16×10 ⁻⁵	3.70	2.82–4.85	1.00×10 ⁻¹³
CFH rs1410996	0.36	0.27–0.48	5.05×10 ⁻¹²	0.23	0.15–0.36	1.28×10 ⁻¹³
CFH rs800292	0.61	0.49–0.75	5.38×10 ⁻⁶	0.70	0.44–1.10	0.12
CFH rs12144939	0.57	0.47–0.71	6.71×10 ⁻⁷	0.51	0.28–0.91	0.02
CFI rs10033900	1.07	0.85–1.35	0.59	0.99	0.76–1.28	0.93
CFI rs141853578	1.17	0.96–1.43	0.12	–*	–*	–*
C2 rs9332739	0.70	0.42–1.17	0.17	–*	–*	–*
C3 rs2230199	1.17	0.96–1.42	0.11	2.17	1.42–3.31	0.0004
C3 rs433594	0.98	0.80–1.21	0.88	0.91	0.67–1.23	0.52
C3 rs6795735	1.10	0.89–1.36	0.37	2.06	1.27–3.33	0.03
CFB rs4151667	0.74	0.52–1.05	0.08	–*	–*	–*
CFB rs641153	0.72	0.54–0.96	0.02	–*	–*	–*
CFD rs3826945	1.01	0.76–1.34	0.94	0.76	0.48–1.22	0.26
LPL rs12678919	1.02	0.80–1.29	0.89	1.11	0.51–2.43	0.79
LIPC rs10468017	0.94	0.78–1.14	0.53	0.63	0.43–0.93	0.19
TIMP3 rs9621532	0.86	0.52–1.42	0.56	–*	–*	–*
APOE2 rs7412	1.21	0.84–1.76	0.31	–*	–*	–*
APOE4 rs429358	0.84	0.60–1.17	0.30	–*	–*	–*
FADS1 rs174547	0.88	0.72–1.06	0.18	0.64	0.46–0.88	0.006
CETP rs2230199	1.39	1.15–1.70	0.001	1.38	1.02–1.87	0.04
TLR rs4986790	1.08	0.71–1.64	0.71	0.53	0.08–3.36	0.50
TLR3 rs3775291	1.00	0.75–1.34	0.99	0.78	0.48–1.27	0.32
SERPING rs2511989	1.10	0.81–1.50	0.53	0.79	0.54–1.16	0.22
ABCA4D2177 rs1800555	0.96	0.33–2.82	0.94	–*	–*	–*
ABCA4G1961 rs1800553	0.88	0.12–6.58	0.90	–*	–*	–*
ABCA4 rs76157638	2.14	0.98–4.67	0.06	–*	–*	–*
VEGFA rs699946	1.08	0.81–1.44	0.61	1.47	0.75–2.89	0.27
SPRYD7 rs7995557	1.01	0.73–1.40	0.95	0.57	0.23–1.43	0.23
COL8A1 rs13081855	1.03	0.80–1.33	0.82	0.53	0.16–1.74	0.30
COL10A1 rs3812111	1.04	0.84–1.28	0.73	1.02	0.75–1.40	0.89
SLC16A8 rs8135665	1.21	0.98–1.49	0.08	1.39	0.87–2.21	0.17
ADAMTS9-AS2 rs6795735	1.21	0.98–1.51	0.08	1.30	0.98–1.72	0.07

[†]Adjusted for age and gender; *analysis not performed due to small group size.
doi:10.1371/journal.pone.0093459.t004

rs6795735 and rs2230199 in *C3*) that had reached statistical significance in the individual analysis and the two major AMD risk SNPs risk *ARMS2* rs10490924 and *CFH* rs1061170. Additionally, age, gender, and smoking status was included. The corrected R-square was 0.063. Adding the AMD status to the model, the corrected R-square was 0.067.

In the second model, *CFH* haplotypes, age, gender, and smoking status were included. The corrected R-square was 0.038.

Discussion

Dysregulation of the alternative complement pathway is thought to play a key role in AMD pathogenesis, which is also reflected by increased systemic complement levels.

In this study we analyzed the association of genetic AMD risk polymorphisms with systemic complement activation. We identified only a few variants in the *CFH*, *CFB*, and *C3* gene that showed an association with systemic complement activation, while for all other genetic polymorphisms associations were not observed.

While the association with genetic polymorphisms was weak, we found a significant association of the phenotype AMD with an increased C3d/C3 ratio which is in line with other smaller studies.[12,13] Our linear model including the AMD phenotype, the two major non-genetic risk factors age and smoking, and eight relevant SNPs could only explain 6.7% of the variation in the C3d/C3 ratio, indicating that these AMD risk polymorphisms do not explain sufficiently increased systemic complement activation found in AMD patients. The inclusion of *CFH* haplotypes in the

model revealed an even lower explanation of the C3d/C3 ratio of only 3.8%.

Our analysis concentrated on C3d as a marker of chronic complement activation because it is a relatively stable protein with a long half-life. To correct for differences in the concentration of the precursor protein, we also measured C3 in the plasma.

CFH, CFB, and C3 influence the regulation of the alternative pathway of the complement system. CFH acts as the major regulator of complement activation controlling the alternative pathway in blood and on cell surfaces [18], and accelerates the decay of the alternative C3 convertase (C3bBb) [19].

CFH is also a cofactor of CFI-mediated cleavage and inactivation of C3b [20]. The formation of C3d, a polypeptide fragment generated during alternative C3 convertase cleaves C3 to C3b, is also CFH dependent [21]. Alterations in the CFH gene may change the regulating characteristics of CFH resulting in an up or down regulation of the CFH dependent elements of the alternative complement pathway. In our cohort, SNPs rs1410996, rs800292, and rs12144939 in the *CFH* gene were associated with lower C3d/C3 ratios and a lower risk for AMD, whereas the most common AMD risk variant rs1061170 was not associated with the C3d/C3 ratio even after stratification in AMD patients and controls. Additionally, *CFH* haplotypes showed lower C3d/C3 ratios in all cases compared to the reference haplotype. Therefore, *CFH* SNPs were not associated with increased systemic complement activation.

CFB is an acute phase protein involved in the alternative complement pathway as a precursor of C3 convertase. CFB is cleaved to Bb which combines with C3b to form the alternative pathway C3 convertase C3bBb. An acute phase response-mediated up-regulation may result in elevated systemic plasma levels of CFB in AMD patients and may contribute to an enhanced systemic complement activity [12,13,22]. In our study we observed lower C3d/C3 ratios for the operatively protective *CFB* variants for AMD indicating that individuals with these polymorphisms show less complement activation.

Among all analyzed SNPs, only variants in the *C3* gene were associated with higher systemic C3d/C3 ratios which aligns with the results by Hecker et al.¹¹ The alternative pathway of the

complement system starts with spontaneous hydrolysis of C3 and variants with a higher risk for AMD seem to influence this part of the complement cascade resulting in elevated systemic complement activation. Scholl et al did not observe a correlation between genetic variants in *C3* and systemic C3d levels¹² underlining that the systemic effects of AMD susceptibility genes on complement activation are only weak.

In our study, slightly higher C3d/C3 levels were found in AMD patients. In order to not miss a combined effect of multiple SNPs, we performed linear models to illustrate the effect of the combination of SNPs on complement activation. These models could not explain the C3d/C3 ratio, showing that there have to be other systemic effects than AMD phenotype or genetic variants influencing systemic complement activation. Hecker et al also showed in a small cohort that risk haplotypes in *CFH* did not alter complement levels, whereas protective haplotypes reduced complement levels including C3d [12].

A limitation of our study is the analysis of only two components of the complement system, which is accompanied by several strengths including a large cohort of well-balanced AMD patients and controls, a high number of investigated SNPs and the use of multimodal imaging that avoids misclassification of phenotypes.

In summary, we showed that the major AMD risk polymorphisms in *CFH* and *ARMS2* are not associated with increased systemic complement activation as measured by the C3d/C3 ratio. Few SNPs were associated with lower levels of systemic complement activation, particularly the *CFH* and *CFB* polymorphisms that are protective against AMD. Only variants in *C3* were associated with elevated complement levels. Furthermore, a model including major genetic and non-genetic factors for AMD was not able to explain complement activation.

Author Contributions

Conceived and designed the experiments: CH ADH SF. Performed the experiments: TR LE MD ADH SF. Analyzed the data: TR CP LE MH YL BK ADH SF. Contributed reagents/materials/analysis tools: MD CH BK ADH SF. Wrote the paper: TR CP LE CH EDJ MD ADH SF.

References

- Seddon JM, Cote J, Page WF, Aggen SH, Neale MC (2005) The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. *Archives of ophthalmology* 123: 321–327.
- Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, et al. (2005) Complement factor H polymorphism and age-related macular degeneration. *Science* 308: 421–424.
- Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, et al. (2006) Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. *Nat Genet* 38: 458–462.
- Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, et al. (2005) Complement factor H variant increases the risk of age-related macular degeneration. *Science* 308: 419–421.
- Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, et al. (2005) Complement factor H polymorphism in age-related macular degeneration. *Science* 308: 385–389.
- Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, et al. (2007) Variation in complement factor 3 is associated with risk of age-related macular degeneration. *Nat Genet* 39: 1200–1201.
- Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, et al. (2007) Complement C3 variant and the risk of age-related macular degeneration. *N Engl J Med* 357: 553–561.
- van de Ven JP, Nilsson SC, Tan PL, Buitendijk GH, Ristau T, et al. (2013) A functional variant in the *CFH* gene confers a high risk of age-related macular degeneration. *Nat Genet* 45: 813–817.
- Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, et al. (2001) An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. *Prog Retin Eye Res* 20: 705–732.
- Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, et al. (2006) Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. *Proc Natl Acad Sci U S A* 103: 17456–17461.
- Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, et al. (2006) Drusen complement components C3a and C5a promote choroidal neovascularization. *Proc Natl Acad Sci U S A* 103: 2328–2333.
- Hecker LA, Edwards AO, Ryu E, Tosakulwong N, Baratz KH, et al. (2010) Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. *Hum Mol Genet* 19: 209–215.
- Scholl HP, Charbel Issa P, Walier M, Janzer S, Pollok-Kopp B, et al. (2008) Systemic complement activation in age-related macular degeneration. *PLoS One* 3: e2593.
- Smailhodzic D, Klaver CC, Klevering BJ, Boon CJ, Groenewoud JM, et al. (2012) Risk alleles in *CFH* and *ARMS2* are independently associated with systemic complement activation in age-related macular degeneration. *Ophthalmology* 119: 339–346.
- Hawkins JR, Khripin Y, Valdes AM, Weaver TA (2002) Miniaturized sealed-tube allele-specific PCR. *Hum Mutat* 19: 543–553.
- Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. *Am J Hum Genet* 68: 978–989.
- Stephens M, Donnelly P (2003) A comparison of bayesian methods for haplotype reconstruction from population genotype data. *Am J Hum Genet* 73: 1162–1169.
- Zipfel PF, Hallstrom T, Hammerschmidt S, Skerka C (2008) The complement fitness factor H: role in human diseases and for immune escape of pathogens, like pneumococci. *Vaccine* 26 Suppl 8: 167–74.
- Khandhadia S, Cipriani V, Yates JR, Lotery AJ (2012) Age-related macular degeneration and the complement system. *Immunobiology* 217: 127–146.

20. Pangburn MK (2000) Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement. *Immunopharmacology* 49: 149–157.
21. Schreiber RD, Pangburn MK, Lesavre PH, Muller-Eberhard HJ (1978) Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. *Proc Natl Acad Sci U S A* 75: 3948–3952.
22. Reynolds R, Hartnett ME, Atkinson JP, Giclas PC, Rosner B, et al. (2009) Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. *Invest Ophthalmol Vis Sci* 50: 5818–5827.